Dynamic Chart
Director TitleAgeSince
Chief Executive Officer - 2024-03-04
Chief Executive Officer - 2024-03-04
Chief Tech/Sci/R&D Officer - 2021-04-30
Manager TitleAgeSince
Director/Board Member 75 1999-07-07
Director/Board Member 52 2021-05-19
Chairman 65 2023-05-28
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-0.45%-1.19%+3.28%-6.37%86.2B
-1.04%-1.25%+34.99%+5.33%47.24B
+1.44%-1.46%+135.49%+84.25%35.8B
+0.73%-2.15%-36.02%-32.31%22.94B
+0.01%-2.85%+27.09%+10.84%13.97B
-0.82%-1.27%+57.39%-37.62%13.25B
-0.69%-0.81%-29.44%-22.29%12.57B
-3.14%-3.14%+323.66%+324.34%11.48B
+0.30%+4.42%-53.26%-64.63%9.89B
Average -0.41%-0.82%+51.46%+29.06% 28.15B
Weighted average by Cap. -0.28%-1.45%+39.14%+17.50%
See all sector performances
Logo Mithra Pharmaceuticals S.A.
Mithra Pharmaceuticals SA is a Belgian biopharmaceutical company dedicated to transforming women's health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra Pharmaceuticals S.A. explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrolbased product in 2021, the contraceptive pill ESTELLE®, Mithra is now focusing on its second product DONESTA®, the next-generation hormone therapy. Mithra Pharmaceuticals S.A. also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO.
Employees
270
More about the company